Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chidamide monotherapy in relapsed or refractory extranodal nasal type NK/T-cell lymphoma
ChiCTR1800015471Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by West China Hospital of Sichuan University. Primary endpoints: Objective response rate, Complete response rate and 1 more. Planned start May 2018; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR1800015471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015471.